Comparing growth velocity of HIV exposed and non-exposed infants: An observational study of infants enrolled in a randomized control trial in Zambia by Chilyabanyama, Obvious Nchimunya et al.
eCommons@AKU 
Department of Paediatrics and Child Health Division of Woman and Child Health 
8-23-2021 
Comparing growth velocity of HIV exposed and non-exposed 
infants: An observational study of infants enrolled in a 
randomized control trial in Zambia 
Obvious Nchimunya Chilyabanyama 
Roma Chilengi 
Natasha Makabilo Laban 
Masuzyo Chirwa 
Michelo Simunyandi 
See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr 
 Part of the Immune System Diseases Commons, and the Pediatrics Commons 
Authors 
Obvious Nchimunya Chilyabanyama, Roma Chilengi, Natasha Makabilo Laban, Masuzyo Chirwa, Michelo 
Simunyandi, Luiza Miyanda Hatyoka, Innocent Ngaruye, Najeeha Talat Iqbal, and Samuel Bosomprah 
RESEARCH ARTICLE
Comparing growth velocity of HIV exposed
and non-exposed infants: An observational
study of infants enrolled in a randomized
control trial in Zambia
Obvious Nchimunya ChilyabanyamaID
1,2*, Roma Chilengi2, Natasha Makabilo Laban2,
Masuzyo Chirwa2, Michelo Simunyandi2, Luiza Miyanda HatyokaID
2, Innocent Ngaruye3,
Najeeha Talat Iqbal4, Samuel Bosomprah2,5
1 African Centre of Excellence in Data Science (ACEDS), University of Rwanda, Kigali, Rwanda, 2 Research
Division, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia, 3 College of Science and
Technology, University of Rwanda, Kigali, Rwanda, 4 Aga Khan University Hospital, Karachi, Pakistan,




Impaired growth among infants remains one of the leading nutrition problems globally. In
this study, we aimed to compare the growth trajectory rate and evaluate growth trajectory
characteristics among children, who are HIV exposed uninfected (HEU) and HIV unexposed
uninfected (HUU), under two years in Zambia.
Method
Our study used data from the ROVAS II study (PACTR201804003096919), an open-label
randomized control trial of two verses three doses of live, attenuated, oral RotarixTM admin-
istered 6 &10 weeks or at 6 &10 weeks plus an additional dose at 9 months of age, con-
ducted at George clinic in Lusaka, Zambia. Anthropometric measurements (height and
weight) were collected on all scheduled and unscheduled visits. We defined linear growth
velocity as the rate of change in height and estimated linear growth velocity as the first deriv-
ative of the mixed effect model with fractional polynomial transformations and, thereafter,
used the second derivative test to determine the peak height and age at peak heigh.
Results
We included 212 infants in this study with median age 6 (IQR: 6–6) weeks of age. Of these
97 (45.3%) were female, 35 (16.4%) were stunted, and 59 (27.6%) were exposed to HIV at
baseline. Growth velocity was consistently below the 3rd percentile of the WHO linear growth
standard for HEU and HUU children. The peak height and age at peak height among HEU
children were 74.7 cm (95% CI = 73.9–75.5) and 15.5 months (95% CI = 14.7–16.3) respec-
tively and those for HUU were 73 cm (95% CI = 72.1–74.0) and 15.6 months (95% CI =
14.5–16.6) respectively.
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Conclusion
We found no difference in growth trajectories between infants who are HEU and HUU. How-
ever, the data suggests that poor linear growth is universal and profound in this cohort and
may have already occurred in utero.
Introduction
Impaired growth among infants remains one of the leading nutrition problems globally. In
2019, the prevalence of stunting among children under 5 years was estimated to be 21.3% (140
million children) globally and 33% (52 million children) in the sub-Saharan Africa region [1].
The global and sub-Saharan prevalence of stunting can be classified as high and very high,
respectively [2]. The Zambia demographic health Survey (2014) (ZDHS) [3] reported a preva-
lence of 40% stunting among children under 5 and 56% for children between 18–23 months.
Impaired growth is associated with an increased risk of mortality and morbidity among infants
[4, 5]. Long-term and short-term effects of poor linear growth on the child included delay in
motor skill development, impaired brain function, poor performance in school, and increased
risk of morbidity and mortality [6, 7].
While several studies have shown a negative relationship between HIV infected children
and attained growth [8–10], there were no studies, to the best of our knowledge, which studied
the relationship between HIV exposure and linear growth velocity. There are concerns that
children who are HIV exposed uninfected (HEU) are at risk of deficiencies in multiple micro-
nutrients that play an important role in child growth and development [11]. Studies have
shown that children who are HEU have an increased risk of mortality and morbidity than chil-
dren who are HIV unexposed uninfected (HUU). This may be due to increased risk of prema-
turity and reduced care due to parental illness or death [12, 13]. Additionally, studies have also
shown that children who are HEU have poor health outcomes compared to children who are
HUU [14].
Characterizing growth trajectories among infants who are HEU is important in designing
interventions aimed at improving the growth of these children. Previous studies investigating
the relationship between impaired growth and HIV exposure have used attained growth for
age, calculated as height for age (HAZ), but this has limitations. A HAZ measurement only
reflects growth from birth to that particular point [15]. This may not give a proper indication
of how the child has been growing. Growth velocity has been identified to be more robust and
can identify growth problems earlier than attained growth for age [16–18].
In this study, we aimed to compare the rate of growth among children who are HEU and
HUU under two years, enrolled in the ROVAS II clinical trial (PACTR201804003096919),
using the World Health Organization (WHO) growth velocity standards (WHO 2009) [19].
We also evaluated growth trajectory characteristics by determining the peak height and age at
which growth begins to falter.
Materials and methods
Study site and population
The University of Zambia Biomedical Research Ethics Committee, and the Zambian Ministry
of Health approved the study. The study was conducted in accordance with the principles of
the Declaration of Helsinki and in compliance with good clinical practice guidelines and is
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registered at ClinicalTrials.gov with registration number PACTR201804003096919. Written
informed consent was obtained from all mothers of participating infants.
The ROVAS II study was conducted at George Clinic in Lusaka, between September 2018
and July 2021, a government health facility where the maternal child health (MCH) depart-
ment, Antiretroviral Therapy (ART) clinic and the Centre for infectious disease research in
Zambia (CIDRZ) research unit are co-located. The health centre catchment population is esti-
mated to be around 145,230 [20]. The study site is a typical peri-urban setting in Lusaka.
Mothers coming for their initial visit at the MCH between September and October 2018 were
given information about the study. Motivated mothers were invited to the research unit, where
informed consent was obtained. All pregnant women attending MCH were tested for HIV,
and those who tested positives were immediately provided with life treatment regardless of
their CD4 count in line with the WHO and national guidelines [21, 22]. Infants born from
HIV positive mothers received the nationally recommended antiretroviral prophylaxis and
were tested routinely at 6 weeks (enrolment), 6 months, 9 months and after cessation of breast-
feeding or at two years of age. Infants who seroconverted for HIV were excluded from this
analysis.
Study design and participants
The ROVAS II is an open-label randomized control trial of two versus three doses of live,
attenuated, oral Rotarix TM administered at 6 &10 weeks and at 6,10, plus 9 months of age.
Infants were enrolled if; their parents consented to participate in the study and were eligible
for Rotavirus vaccine immunization as per national immunization policy. Mothers were will-
ing to have the child undergo study procedures such as full-course vaccination protocol
anthropometric measurements and sample collection.
Anthropometrics measurements were collected according to the standard procedures by
trained study nurses. Recumbent length was measured to the nearest 0.1 cm using a horizontal
measuring board with a sliding foot piece. Infant’s weight and height were collected monthly
from 6 weeks of age to 24 months as scheduled, but in addition to the scheduled visit, these
measurements were collected each time the child was unwell and brought to the clinical
research site.
Statistical analysis
Summary statistics (mean and proportions) were used to describe participant’s baseline char-
acteristics. This included infant age at the first visit, gender, birth weight, mother’s age at
infant’s birth, maternal HIV status at infant’s birth, and HAZ. We calculated HAZ for each
baseline height measurement available for each child using the WHO child growth standards
WHO 2006 [23]. Stunting was defined as HAZ< − 2. Based on this cut-off, we calculated the
proportion of children who were stunted at enrolment. We defined linear growth velocity as
the rate of change in height. We included children who had at least three height measurements
in the analysis.
We calculated growth velocity using two approaches. First, we calculated empirical growth
velocity for each child as the difference between two successive height measurements divided
by the corresponding age gap. We calculated the average 3-monthly age-specific growth veloc-
ity and 95% confidence interval (CI) using these values. The actual ages at which measure-
ments were made were at times delayed (or advanced) compared to the target ages based on
scheduled visits. This resulted in some measurement intervals being either longer or shorter
than 91 days for a 3-month interval [24]. For this reason, we corrected the actual measurement
age to target age using maximum tolerable difference. We adjusted standard errors for
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clustering of measurement within each child. The velocity and 95%CI for each age gap were
presented using range plots for the entire sample and by sex and HIV exposure status.
Secondly, we estimated linear growth velocity as the first derivative of the mixed effect
model with fractional polynomial transformations [25–27]. To account for the non-linear rela-






Where H1ðxÞ ¼ xðp1Þ and for j = 2,. . ., m,
HjðxÞ ¼
xpj ; pj 6¼ pj  1
Hj  1ðxÞlnðxÞ; pj ¼ pj  1
(
Where ps are exponents selected from a sample space {-2, -1, -0.5, 0, 0.5, 1, 2, 3}.
The model assumes that x should be monotonically increasing, an assumption that holds
true for infant height. We selected a parsimonious fractional polynomial model based on mini-
mal deviance, according to a closed test procedure called the fractional polynomial selection
procedure or function selection procedure as described in [25, 28]. This procedure is described
further in Raysto (1990) [29].
After selecting the model, we fit the model in a mixed effect framework, and controlled for
mother’s age, HIV exposure status, mothers’ education, mothers’ marital status, number of sib-
lings, gestational age and gender to obtain predicted height for each child at each age. We then
estimated the growth velocity as the numerical first derivative of the predicted height with
respect to infant’s age. To characterize growth trajectory in terms of peak height and age at age
growth begins to falter, we used the second derivative test. Infants who had less than three
height measurements were excluded from the analysis due to the inability to calculate the rate
of change of height over the duration of the study. The age and the height at that age were sum-
marized to describe the trajectory characteristics. All analyses were performed using Stata 16.0
MP (Stata Corp, College Station, TX, USA).
Results
Characteristics of infants
The main study enrolled 214 infants aged between 5 and 11 weeks. We included 212 infants in
this study after excluding 10 infants who were lost to follow up 2 who seroconverted for HIV
during follow up. Hundred and sixteen (54.7%) infants enrolled were male while 96 (45.3%)
where female, and 57 (26.9%) were HIV exposed. The median age of the mothers was 25 (IQR:
21–29). Hundred and twenty (56%) of the mothers had attained primary school education,
while 39 (18%) and 53 (25%) had secondary or post-secondary education and no formal edu-
cation, respectively. Most mothers, 174 (84%), were married, and only 34 (16%) were not mar-
ried. Thirty-five (16.4%) infants were stunted (HAZ < -2) at enrolment, and there were no
statistical differences in the level of stunting by mothers’ and infants’ demographic characteris-
tics (Table 1).
Growth velocity among HIV exposed and unexposed infants
The 3 monthly average growth velocity is monotonically reducing over time. Between 0 and 6
months, the 3 monthly growth velocity is higher among infants who are HUU compared to
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those who are HEU. However, the difference is not statistically significant as all the 95% CI are
overlapping and all p values based on a t test are non-significant (see Fig 2). Growth velocity
was consistently below the 3rd percentile of the WHO linear growth standard for boys who are
HEU and HUU and for girls who are HEU and HUU see Fig 1, suggesting that growth retarda-
tion is universal in our cohort. There was no statistical difference in 3 monthly growth velocity
between infants who are HEU and HUU at all time points as p values >0.05 see Table 2 below.
A fractional model of order p1 = 0 (log age) and p2 = 3 was selected against higher-order
polynomials, using minimum deviance criteria. Thus, we fit a mixed effect model of the form;
heightij ¼ b1 logðageijÞ þ b2 age
3
ij þ b3hiv exposureþ b4 mother eductaioni þ b5 mother
0s agei
þ b6 mother
0s marital statusþ b7 simblingsi þ uj þ εij
Where i and j are visit and infants, respectively, the error terms from our model follow a
gaussian distribution as can be seen in S1 Fig. There was no correlation between the predicted
values residuals and the residual where normally distributed, as can be seen in S2 Fig. Further,
visualization of individual growth shows that our model reflects both individual and popula-
tion growth.
The estimated peak height and age at peak height were 73.8484 cm (95% CI = 14.91–16.13)
and 14.6 months. This can be supported by the near-flat slight line after age month 144.5, as
shown in Fig 2C. The predicted growth trajectory is between infants who are HUU and those
who are HEU is similar as can be seen in Fig 2B. The height and age at peak height among
Table 1. Infant nutritional status by background characteristics.
n (%) of Total n (%) Not Stunted n (%) Stunted p value
Hiv Exposure
not exposed 155 (73.1) 132 (85.2) 23 (14.8) 0.171
exposed 57 (26.9) 44 (77.2) 13 (22.8)
Gender
Female 96(45.3) 85(88.5) 11 (11.5) 0.051
Male 116(54.7) 91(78.4) 25 (21.6)
Gestation
full term 198(93.4) 168(84.8) 30(15.2) 0.008
preterm 14(6.6) 8(57.1) 6(42.9)
Number of Siblings
1 61(28.8) 47(77) 14(23) 0.184
2–4 129(60.8) 112(86.8) 17(13.2)
5 and above 22(10.4) 17(77.3) 5(22.7)
Mother’s age
<24 99(46.7) 81(81.8) 18(18.2) 0.268
24–35 100(47.2) 86(86) 14(14)
36 and above 13(6.1) 9(69.2) 4(30.8)
Mother’s Education
No formal education 53(25) 43(81.1) 10(18.9) 0.521 1
Primary education 120(56.6) 98(81.7) 22(18.3)
Secondary and post-secondary secondary 39(18.4) 35(89.7) 4(10.3)
Mother’s Marital
Single 35(16.5) 28(80) 7(20) 0.603
Married 177(83.5) 148(83.6) 29(16.4)
Total 212(100) 176 (83) 36(17)
https://doi.org/10.1371/journal.pone.0256443.t001
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infants who were HEU 14.74 months (95% CI = 14.35–5.14) and 73.16 cm (95% CI = 72.72–
73.60) respectively and those for HUU were 14.48 months (95% CI = 14.12–14.84) and 74.16
cm (95% CI = 73.75–74.50) respectively. There is no statistical difference between the peak
height and age at peak height between infants who are HEU and HUU, as can be supported by
overlapping confidence intervals.
Discussion
Our study showed no significant difference in the growth rate between infants who are HEU
and HUU in our cohort, similar to the findings in Ross et al. (1995) [30]. Secondly, our study
showed no association between baseline stunting and a child’s HIV exposure status in our
cohort. Thirdly, we found that there is early linear growth faltering in infants both HEU and
HUU. The growth velocity percentiles in the cohort were below the WHO 3rd percentile,
Fig 1. Three-monthly empirical linear growth velocity. In green are the WHO linear growth velocity standard (3rd and 97th percentiles), In blue is the three-monthly
empirical growth of infants who are HIV unexposed and uninfected, while in red is the empirical growth of infants who are HIV exposed and uninfected with a 95%
Confidence interval (CI). Overall growth velocity average per 3 months’ time by HIV exposure (a); Average growth velocity per 3 months for the boys (b); Average growth
exposure for girls (c).
https://doi.org/10.1371/journal.pone.0256443.g001
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indicating poor growth among infants who are HEU and HUU [31], our finding is similar to
the finding of Chilengi et al. (2019). In our cohort, growth rate falters around 15 months in
both infants who are HEU and their HUU counterparts, slightly higher than 13.6 months as
reported in a similar study [32].
The consistently lower growth velocity among infants in our cohort could be an indication
of poor maternal nutrition [31]. It is suggestive that programmes aimed at averting poor
growth among infants may should perhaps start during a mother’s pregnancy. Therefore, we
Fig 2. Observed and predicted linear growth mixed-effects model. Legend: in red and blue are average predicted growth
curves for infants who are HUU and those who are HEU, respectively. Observed and predicted linear growth curves for all
children (a); Observed and predicted mean linear growth for infants HUU and HEU (b). Observed and predicted linear
growth velocity for infants who are HUU and HEU (c).
https://doi.org/10.1371/journal.pone.0256443.g002
Table 2. Growth velocity for 3 months length increments.
Total Infants who are HUU Infants who are HEU p value 1
GV cm/3 mo, (95% CI) GV cm/3 mo, (95% CI) GV cm/3 mo, (95% CI)
0–3 months 3.48 (3.18–3.79) 3.65 (3.26–4.04) 3.08 (2.6–3.55) 0.11
3–6 months 2.4 (2.29–2.52) 2.45 (2.31–2.6) 2.28 (2.12–2.44) 0.14
6–9 months 1.11 (0.99–1.22) 1.11 (0.98–1.25) 1.09 (0.89–1.29) 0.90
9–12 months 1.08 (0.98–1.19) 1.05 (0.93–1.17) 1.17 (0.98–1.36) 0.24
12–15 months 0.65 (0.53–0.76) 0.7 (0.57–0.84) 0.53 (0.31–0.74) 0.16
15–18 months 0.84 (0.77–0.91) 0.83 (0.75–0.91) 0.88 (0.74–1.01) 0.84
18–21 months 0.79 (0.7–0.89) 0.84 (0.73–0.94) 0.7 (0.51–0.89) 0.29
21–24 months 0.72 (0.62–0.81) 0.69 (0.57–0.8) 0.78 (0.61–0.95) 0.42
1 T-test
Where GV: Growth velocity CI: Confidence Interval and mo: months
https://doi.org/10.1371/journal.pone.0256443.t002
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advocate a need for studies that will focus on feeding practices among breastfeeding HIV
infected mothers and HIV uninfected mothers. Several studies have suggested that an infant’s
growth velocity may be affected by maternal nutrition status and duration of breastfeeding
[33, 34]. That being the case, we are confident these findings would complement our findings.
Our study used fractional models because these models have been found to be more parsi-
monious compared to ordinary conventional polynomials [35]. Further, conventional polyno-
mial models assume a smooth, monotonic curve between infants height and age. In contrast,
other models such as splines or broken stick models assume a piecewise relationship between
infants height and age, which is a biologically implausible relationship [36]. These models have
been applied in longitudinal studies using the multilevel frames in studies on early growth tra-
jectories [37] and BMI trajectories [38].
Our study has many strengths, such as repeated diverse anthropometric measures among
comparable groups of infants who are HEU and HUU. To the best of our knowledge, this is a
detailed description of growth trajectories among infants who are HEU and HUU in the same
setting, in the duration of follow up, frequency of anthropometric assessment among infants.
However, sample size limitations could result in low power and failure to identify true differ-
ences and associations. This study was conducted in George, a peri-urban area in Lusaka, and
participants were not randomly selected. As a result, these results may not be generalizable to
the rural populations. A post hoc sample size calculation based on [39, 40] indicates that our
study achieved a power of 70% when using a Chi-squared test with 1 degree of freedom from a
GEE analysis to determine whether the group slopes differ significantly at a significance level
of 0.050 for 2 groups assuming each is measured 20 times. To achieve the power of 80,% the
study needed to have enrolled 73 infants who are HUU and 145 infants who are HEU. Despite
not collecting data on breastfeeding practices at each follow-up, all mothers in the study were
breastfeeding at baseline and throughout the study as breast milk samples were collected at
each visit. The national and WHO guidelines on HIV places no limit on the duration of breast-
feeding among HIV positive women.
Since this study is observational, we note that there may be residual confounding social-
economic factors, behavioural differences, or direct biological effect of HIV exposure on
infant’s growth that ware not considered during the study’s design.
Despite demonstrating that infants who are HUU and HEU have similar growth patterns,
the ROVAS II study was not initially designed to collect anthropometric data. The study did
not collect data on how long an infant’s mother had been on anti-retroviral treatment (ART)
or their viral suppression status. Duration on ART and viral suppression may be an important
indicator of the mother’s quality of life, affecting the child’s growth.
Conclusion
Our study showed no differences in the peak height velocity and age at peak height between
HEU and HUU infants enrolled in the ROVAS II study. Further, we showed that the func-
tional polynomial model of order 0 and 3 was the best fit model to describe linear growth
among infants in our study. We also found a slower rate of growth and a high prevalence of
stunting among Zambian infants. The data suggests that poor linear growth is universal and
profound in this cohort and may have already been occurring before birth.
Supporting information
S1 Fig. Distribution of the error term of the mixed effect model.
(TIF)
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S2 Fig. Correlation between residuals and the fitted values.
(TIF)
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